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Abstract
Background: Insulin resistance is manifested in muscle, adipose tissue, and liver and is associated with adipose tissue
inflammation. The cellular components and mechanisms that regulate the onset of diet-induced insulin resistance are not
clearly defined.
Methodology and Principal Findings: We initially observed osteopontin (OPN) mRNA over-expression in adipose tissue of
obese, insulin resistant humans and rats which was normalized by thiazolidinedione (TZD) treatment in both species. OPN
regulates inflammation and is implicated in pathogenic maladies resulting from chronic obesity. Thus, we tested the
hypothesis that OPN is involved in the early development of insulin resistance using a 2–4 week high fat diet (HFD) model.
OPN KO mice fed HFD for 2 weeks were completely protected from the severe skeletal muscle, liver and adipose tissue
insulin resistance that developed in wild type (WT) controls, as determined by hyperinsulinemic euglycemic clamp and
acute insulin-stimulation studies. Although two-week HFD did not alter body weight or plasma free fatty acids and
cytokines in either strain, HFD-induced hyperleptinemia, increased adipose tissue inflammation (macrophages and
cytokines), and adipocyte hypertrophy were significant in WT mice and blunted or absent in OPN KO mice. Adipose tissue
OPN protein isoform expression was significantly altered in 2- and 4-week HFD-fed WT mice but total OPN protein was
unchanged. OPN KO bone marrow stromal cells were more osteogenic and less adipogenic than WT cells in vitro.
Interestingly, the two differentiation pathways were inversely affected by HFD in WT cells in vitro.
Conclusions: The OPN KO phenotypes we report reflect protection from insulin resistance that is associated with changes in
adipocyte biology and adipose tissue inflammatory status. OPN is a key component in the development of HFD-induced
insulin resistance.
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Introduction
Insulin resistance associated with obesity, aging, and type 2
diabetes is an increasingly prevalent disease that affects skeletal
muscle, liver, adipose tissue, and immune cells. In human and
rodent models, obesity and insulin resistance are associated with
macrophage infiltration and inflammation in the adipose tissue
involving the secretion of inflammatory cytokines [1–3]. Adipose
tissue inflammation impairs insulin signaling through negative
feedback via cytokine-activated JNK, IKKb and SOCS pathways
[1]. Thiazolidinediones (TZDs) are used to treat insulin resistance
in a variety of pathological states, including type 2 diabetes,
polycystic ovary syndrome, and ‘‘syndrome X’’ [4,5]. TZDs are
ligands for peroxisome proliferator-activated receptor gamma
(PPARc), which is critical for maintaining proper metabolism in
insulin target tissues [6]. PPARc regulates the expression of many
genes although the exact PPARc target genes that modulate
insulin sensitivity are as yet unidentified.
High fat diet (HFD) feeding is a common mode of inducing
insulin resistance in rodents that rapidly causes progressive
metabolic dysfunction [7,8]. Insulin resistance in heart, adipose
tissue, liver, and muscle, adipose tissue hypertrophy and
inflammatory cell infiltration, and hyperinsulinemia are robustly
observed as early as 1–3 weeks of HFD, with minimal to no total
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these phenotypes are much more pronounced and accompanied
by other severe metabolic dysregulation including dyslipidemia &
ectopic triglyceride storage, hypo-adiponectinemia, adipose tissue
hypoxia, cell death and remodeling, beta-cell decompensation,
mild hyperglycemia, and deterioration of cardiac function
[7,8,11]. The key molecules involved in the early stages of HFD-
induced insulin resistance and adipose tissue inflammation and
macrophage infiltration are not well characterized. Recent studies
suggest an important role for osteopontin (OPN) in insulin
resistance and macrophage recruitment to and regulation of
inflammation in vascular and adipose tissue [14,15].
OPN is a secreted, extracellular matrix-associated protein, with
diverse biological activities many of which make it interesting for
study in relation to insulin resistance and type 2 diabetes ([16,17]
and references within). For example, OPN is involved in cell
migration and adhesion, macrophage activation, inflammation,
tissue calcification, and matrix remodeling [18]. OPN is over-
expressed in many pathophysiological states associated with insulin
resistance and type 2 diabetes, such as, in the aorta of
hyperglycemic diabetics, atherosclerotic lesions, activated macro-
phages, steatotic hepatitis, end-stage kidney failure, and osteopo-
rosis. Positive regulators of OPN expression include cytokines, e.g.,
IL-6, IL-1b, INF-c, TNFa, LPS, leptin, and angiotensin II,
reactive oxygen species, and hypoxia [17–19], which dampen
insulin sensitivity. PPARc and/or LXR ligands have been shown
to antagonize OPN expression in obese human adipose tissue [20],
macrophage models [19,21], mouse aorta [22], and fibroblasts
over-expressing ectopic PPARc together with an OPN promoter-
driven reporter gene [15]. OPN is extensively and heterogeneously
spliced, translated, phosphorylated, glycosylated, and proteolysed
[23–25]. Post-translational modification and isoform expression of
OPN varies by pathological state and cell type and differentially
modulates its biological activity [23–28]. OPN binds to integrins
and CD44 through which it can signal to downstream targets
including phosphatidylinositol 3-kinase (PI3K), src kinase, and
NFkB. OPN has been shown to be over-expressed in obese
adipose tissue and adipose tissue macrophages from rodents and
humans [20,27] and is important for insulin resistance and adipose
tissue macrophage infiltration after very long-term HFD (25
weeks) [15]. Given that OPN is a cytokine and regulator of cell
migration and inflammation, OPN may play a role in the early
development of insulin resistance.
In the current study, we measured OPN expression in adipose
tissue from lean and obese rats and humans, before and after TZD
treatment and found that OPN levels were increased with insulin
resistance and normalized by TZD treatment. In order to
investigate the role of OPN in the early onset of diet-induced
insulin resistance, we compared wild type (WT) and OPN knockout
(OPN KO) mice fed normal chow (NC) or HFD for 2–4 weeks.
OPN KO mice fed NC had greater hepatic insulin sensitivity than
WT mice and were protected from 2 week HFD-induced insulin
resistance in skeletal muscle, liver, and adipose, as measured by
hyperinsulinemic-euglycemic clamp and by insulin-stimulated Akt
phosphorylation. Two week HFD increased plasma leptin levels,
adipose tissue macrophages and cytokines, and adipocyte size in
WTmice buttheseeffectswereabsentorblunted inOPNKOmice.
Short-term high fat feeding in WT mice was associated with altered
OPN isoform expression but not change in total protein. Both HFD
and OPN KO caused alterations on adipogenic and osteogenic
potential of bone marrow stromal cells in vitro. Our studies
demonstrate that OPN is required at an early stage of HFD-
induced insulin resistance, before the onset of many pathophysio-
logical features characteristic of extended high fat feeding.
Materials and Methods
Human sample studies
Archival samples of human adipose tissue RNA isolated during
the course of a prior clinical study were used [20]. Subject-
matched clinical data associated with the adipose tissue samples
were compiled herein and correlated with OPN mRNA expression
data. In the prior study, five lean, insulin sensitive and six obese,
insulin resistant subjects were treated with pioglitazone (45mg/
day) for three months. Clinical characteristics of the subjects are
shown in Table 1. Before and after pioglitazone treatment, a
subcutaneous adipose tissue biopsy was harvested from each
subject and flash-frozen in liquid nitrogen, just prior to a 5 hr
60mU/m
2/min hyperinsulinemic-euglycemic clamp study. Base-
line plasma samples were drawn and hyperinsulinemic-euglycemic
clamps were performed in the morning after a 10 hr fast as
previously described [20]. The experimental protocol and sample
studies were approved by the Institutional Review Board of the
University of California, San Diego Human Research Protections
Program. Informed written consent was obtained from each
subject.
Animal strains
Male C57Bl/6J WT mice (cat#000664) and OPN KO mice
(B6.Cg-Spp1
tm2blh/J, cat#004936) were purchased from Jackson
Laboratories. The OPN KO mouse line has been backcrossed into
the C57Bl/6J background .10 generations. Mouse diets were as
follows: normal chow diet (12% kcal from fat; Purina 5001,
LabDiet) and high fat diet (41% kcal from fat; TD96132, Harlan
Teklad or, for SVC studies only, 60% kcal from fat; D12492,
Research Diets). Mice were 4–6 months of age and age-matched
in all studies. Archival tissue samples rat adipose tissue RNA
samples from a larger study were used and group-matched clamp
data associated with the adipose tissue RNA samples were
compiled herein. In the original study, male lean Zucker (fa/+)
and fatty Zucker (fa/fa) rats were used (Charles River). Lean rats
were fed normal chow, fatty rats were fed normal chow or normal
chow dosed to deliver 10 mg/kg/day pioglitazone for three weeks.
All rats were nine weeks of age at time of terminal metabolic
studies and tissue harvest. All animals were housed under
controlled light (12:12 light:dark) and climate conditions. Animals
had unlimited access to food and water. All procedures were
performed in accordance with the Guide for Care and Use of Laboratory
Animals of the National Institutes of Health and were approved by
the University of California, San Diego, Animal Subjects
Committee (protocol #s S02217, S00011, S99173).
In vivo metabolic studies in rats
Insulin sensitivity was determined by hyperinsulinemic-eugly-
cemic clamp, as previously published [29,30]. A variable infusion
of glucose (50% dextrose; Abbott Laboratories) was used, along
with an infusion of tracer (0.16 mCi/min) and insulin (25 mU/
kg
/min, Novlin R; Novo Nordisk, Copenhagen). At the end of the
clamp procedure, the animals were administered a lethal injection
of sodium pentobarbital (100 mg/kg; Nembutal; Abbott Labora-
tories). Plasma glucose specific activity was measured after
deproteinization with barium hydroxide and zinc sulfate [31].
Hepatic glucose output (HGO) and glucose disposal rate (GDR)
were calculated for the basal period and the steady-state portion of
the glucose clamp using the Steele equation for steady-state
conditions [32]. Matched rat groups not subjected to hyperinsu-
linemic-euglycemic clamp studies were used for adipose tissue
analyses. Tissues from these rats were excised after lethal injection,
OPN and Insulin Resistance
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for subsequent in vitro analyses.
In vivo metabolic studies in mice
Insulin sensitivity was assessed using a submaximal hyperinsu-
linemic euglycemic glucose clamp technique and acute insulin
stimulation as previously described [12]. During the clamp studies,
glucose tracer was infused at 2 mCi/hr and insulin was infused at
3 mU/kg/min. The mice were conscious during the clamp and
fully recovered after the procedure. Four days later, mice were
fasted for 5 hr, anesthetized (isoflurane) to collect blood (cardiac
puncture), and then euthanized (pentobarbital) to collect gastroc-
nemius muscle, liver, epididymal and subcutaneous adipose tissue.
Portions of each tissue sample were flash-frozen in liquid nitrogen
or fixed in Zn-formalin. Plasma glucose specific activity, GDR,
and HGO were calculated as described above. Acute insulin
stimulation was achieved by intraperitoneal injection of 6 hr-fasted
mice (0.85 U/kg insulin). After 15 min., the mice were sacrificed
and tissues were harvested as described above.
Plasma and tissue analyses
Plasma insulin concentration was measured using the Insulin
Ultrasensitivie (Mouse) EIA kit (Alpco, Inc.). Plasma FFA levels
were measured enzymatically using a commercially available kit
(NEFA C; Wako Chemicals USA). Triglycerides were measured
using the Triglyceride-SL Assay (Diagnostic Chemicals Ltd.).
Cholesterol was measured using the Chol kit and Roche/Hitachi
analyzer (Roche). Other plasma and tissue lysates components
were analyzed by SDS-PAGE-western blotting-chemilumines-
cence and ELISA. Total and serine-phosphorylated Akt were
measured by western blotting (antibodies from Cell Signaling) and
ELISA (Meso Scale Discovery). Plasma leptin, resistin, ACRP30,
Mcp-1, and OPN (plasma and tissue) levels were determined by
ELISA (R&D Systems). Western blotting was also used to measure
tissue OPN (antibody developed by J.C. at Pfizer) and RBP4
(Adipogen, Inc.). Signal intensities of chemiluminescence autora-
diographs were densitometrically quantified using a digital Kodak
3D Imagestation and associated digital image analysis software
(Kodak,). IL-1b, IL-12p70, IFNc, IL-6, IL-10, Cxcl1 and TNFa
levels in plasma and tissue lysates were measured using a multiplex
(7-plex) ELISA (Meso Scale Discovery).
Fluorescence-activated cell sorting (FACS) of adipose
tissue SVCs
Adipose tissue stromal vascular cells (SVCs) were isolated and
analyzed by FACS as previously reported [11,12] with minor
modifications. Briefly, freshly harvested epididymal fat pads were
separately rinsed and minced in DPBS +1% BSA then treated with
1mg/mL type II collagenase (Sigma) for 25 min in a 37uC shaking
water bath. Adipose tissue cell suspensions were filtered through
100 mm mesh. SVCs were separated from floating adipocytes by
centrifugation, incubated in RBC lysis buffer (eBioscience) for
5 min, then re-suspended in fresh DPBS +1% BSA. SVCs were
incubated with Fc Block (BD Biosciences) for 15 min and then
stained for 30 min with fluorescent-conjugated antibodies against
F4/80 (Ab Serotec), CD11b (BD Biosciences), and CD11c (BD
Biosciences). Cells were washed two times and re-suspended in
DPBS +1% BSA and propidium iodide (Sigma). Presence of the
fluorescent stains in the SVCs was analyzed using a FACS Calibur
flow cytometer (BD Biosciences). Control SVCs preparations,
including unstained cells, PI-only stained cells, and fluorescence-
minus-one (FMO) stained cells, were used to set gatings and
compensation.
Adipocyte sizing
Excised fat pads were immediately fixed in Zn-formalin
overnight, transferred to 70% ethanol, and subsequently paraf-
fin-embedded. Paraffin sections stained with hematoxylin and
Table 1. Clinical Characteristics.
Zucker Rats Lean, no Rx Obese, no Rx Obese, post-Rx
All male, 9 weeks of age, n=7 per group
Weight (g) 23666 363617* 387614*
Fasting plasma glucose (mg/dL) 117.464.4 137.168.6* 124.864.0
Glucose disposal, Rd (mg/kg/min) 38.462.9 18.062.3* 30.662.9
#
Fasting plasma insulin (pmol/L) 1.360.2 24.765.8* 4.861.4*
#
Fasting plasma free fatty acids (mmol/L) 1.5961.4 2.8960.94 0.6960.29*
#
Fasting plasma triglyceride (mg/dL) 44.765.1 276.7654.4* 108.0616.1*
#
Human Patients Lean, pre-Rx Lean, post-Rx Obese, pre-Rx Obese, post-Rx
Gender (male/female) 4/1 5/1
Age (years) 45.268.7 53.862.1
BMI (kg/m
2) 23.161.0 23.661.2 36.362.3* 37.263.2*
Fasting plasma glucose (mg/dL) 90.463.6 87.663.1 97.764.5 91.762.5
Glucose disposal, Rd (mg/kg/min) 11.761.1 10.660.8 4.260.4* 5.960.5*
#
Fasting plasma insulin (pmol/L) 10.361.4 10.162.2 22.163.9* 13.661.6
#
Fasting plasma free fatty acids (mmol/L) 423690 414690 441643 434659
Fasting plasma triglyceride (mg/dL) 88.663.7 76.069.2 182.3642.2 137.767.2*
Data are averages 6 standard error. Rats were treated with pioglitazone for 3 weeks, humans were treated with pioglitazone for 3 months.
*p,0.05 vs. lean subjects.
#p,0.05 vs. pre-Rx subjects. Rx - pioglitazone treatment.
doi:10.1371/journal.pone.0013959.t001
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[33]. All digital images of tissue sections were captured using the
same microscope magnification. Microscopic fields with minimal
non-adipocyte material were selected for quantitation of cell
number per field. There was no apparent difference in non-
adipocyte material in the sections between the mouse groups.
Three fields were captured per mouse fat pad, from five mice in
each group. Section images were visualized and cells per field
image counted using ImageJ software (NIH freeware). Adipocyte
size is represented by the inverse of the adipocyte number per
field.
Isolation and differentiation of plastic-adherent bone
marrow stromal cells (BMSCs)
Mouse femurs were flushed with 1% FCS- containing DMEM
low glucose medium. The washed bone marrow cells from the
femurs were centrifuged for 10 min at 5006g and cultured for 14
days in Basal Mesenchymal Stem Cell (MSC) medium (Cambrex)
supplemented with 1% glutamine (w/v), 100 U/ml Penicillin,
50 mg/ml Streptomycin, and 10% FCS. Differentiation of cultured
BMSCs was conducted as previously described [34,35] with slight
modifications. For adipogenic differentiation, the BMSCs were
plated in monolayer in MSC medium with the addition of 0.5mM
dexamethasone, 50mM indomethacin and 0.5mM IBMX. The
cells were grown for the days indicated and the media was
replaced every three days. For osteogenic differentiation, BMSCs
were plated in monolayer in aMEM medium containing 10%
FCS, 0.5mM dexamethasone, 50mg/ml ascorbic acid, 10mM b-
glycerophosphate and grown as above.
RNA isolation and quantitation
Total RNA was isolated from human adipose tissue, mouse
adipose tissue stromal vascular cells (SVCs) and mouse BMSCs
using Trisol (Invitrogen), and from rat adipose tissue using the
RNeasy Lipid Tissue Kit (Qiagen). Human and rat adipose tissue RNA
quantitation: One step quantitative real-time PCR was carried out
on 10 ng RNA. Primers and probes used were as follows:
humanOPN: forward, 59-AGTTTCGCAGACCTGACATC-
CAGT-39; reverse, 59-TTCATAACTGTCCTTCCCACGGCT-
39; probe, 59FAM-TGGAAAGCGAGGAGTTGAATGGTGCA-
TAMRA-39; ratOPN: forward, 59- TATCAAGGTCATCC-
CAGTTGCCCA-39; reverse, 59- ATCCAGCTGACTTGACT-
CATGGCT-39; probe, 59-FAM-TCTGATCAGGACAG-
CAACGGGAAGA-TAMRA-39. Reactions were run on a 7900
Real-Time PCR System (Applied Biosystems) in a final volume of
20 ml containing 400 nM of the forward and reverse primers,
200 nM probe, 16 iScript Reverse Transcriptase and 16 iTaq
RT-PCR Master Mix (BioRad). Reactions were performed in
triplicate. Cycling parameters were as follows: 50uC for 10 min
and 95uC for 5 min, followed by 40 cycles at 95uC for 10 sec and
60uC for 30 sec. Absolute quantitation was achieved by comparing
to an OPN standard curve constructed using human or rat
Universal Reference RNA standard (Stratagene). The standard
curves had r
2 values of at least 0.99. GAPDH expression was used
to confirm equal sample loading. Mouse adipose tissue SVC and BMSC
RNA quantitation: RNA isolated from SVCs and BMSCs was
converted into cDNA using reverse-transcriptase and dNTPs. For
qPCR, 1 mL of a 25-fold dilution of the cDNA from specific
reverse transcription reactions (above) was amplified using the
LightCycler FastStart DNA MasterPlus SYBR Green I kit (Roche
Diagnostics) with addition of 0.5 mM of each primer in the
LightCycler 2.0 (Roche Diagnostics). Following amplification, a
monocolor relative quantification of the target gene and reference
GAPDH analysis was done to determine the normalized target
gene/GAPDH mRNA copy ratios by the manufacturer’s Light-
Cycler Software (Version 4.0). The following primers were used:
mouse GAPDH: forward 59-CATCCCAGAGCTGAACG- 39,
reverse 59-CTGGTCCTCAGTGTAGCC-39; mouse OSX: for-
ward 59-CTCTCTTTGTCAAGAGTCTTAGC-39, reverse 59-
AGAAAGATTAGATGGCAACGAGTTA-39; mouse PPARc:
forward 59-AGAGTCTGCTGATCTGCG-39, reverse 59-TC-
CCATCATTAAGGAATTCATGTCGTA-39; mouse Akap2:
forward 59-AGACACAAGCATTCCCACTAT-39, reverse 59-C-
ACCATCTCGGAGACCG-39; mouse OPN: forward 59- AGC-
CACAAGTTTCACAGCCACAAGG- 39, reverse 59- CTGA-
GAAATGAGCAGTTAGTATTCCTGC-39. Primers for BMSC
experiments were designed using the LightCycler Probe Design
Software 2.0.
Statistical analyses
Student’s t test and ANOVA (with Tukey’s post hoc test) were
used for statistical analyses. P values for correlations were
determined by linear correlation analysis (GraphPad Prism) using
2-tailed Pearson correlation coefficient. A p value cutoff of 0.05
was used to determine statistical significance.
Results
OPN is over-expressed and down-regulated by TZD
treatment in human and rodent models of insulin
resistance
In the course of extensive microarray analyses of gene
expression alterations associated with insulin resistance in adipose
tissue from lean and obese humans and rats, we identified OPN as
up-regulated in obesity and a TZD target gene [20,30]. Herein, we
used quantitative RT-PCR to compare OPN expression in adipose
tissue from lean and obese humans and rats, before and after
treatment with the TZD pioglitazone. Peripheral insulin sensitivity
(rate of glucose disposal, Rd) of the rat and human groups was
measured using the hyperinsulinemic euglycemic clamp method.
Clinical characteristics of the rats and human subjects are detailed
in Table 1. OPN expression in adipose tissue was elevated in
obese, insulin resistant rats (17-fold) and humans (4.6-fold)
compared to insulin sensitive lean controls (Figure 1A&B).
Pioglitazone treatment improved insulin sensitivity in the obese
rats and human subjects (Table 1) and normalized OPN
expression in the adipose tissue from both species (Figure 1A&B).
Notably, there was a significant correlation between adipose tissue
OPN RNA levels and Rd in the combined, pre-treatment subject
data (Figure 1C). Others report that adipose tissue OPN is over-
expressed in obese humans and mice and in four genetic mouse
models of obesity [15,27,36,37]. Based on our own cross-species
observations in obese human and rat models, we investigated the
role of OPN in the development of insulin resistance.
OPN KO mice are protected from HFD-induced insulin
resistance
We studied the in vivo effects of whole-body OPN gene knockout
in early onset, diet-induced insulin resistance using C57BL/6 WT
and strain-matched OPN KO mice. We conducted euglycemic
hyperinsulinemic clamp studies on WT and OPN KO mice fed
normal chow (NC) or high fat diet (HFD) for two weeks. We
observed significant differences in clamp data from the mouse
strains fed either diet, reflecting greater insulin sensitivity in the
OPN KO mice (Figure 2A–C). In the NC-fed groups, the average
glucose infusion rate (Ginf) during the clamp was 27% greater in
the OPN KO mice compared to WT mice and the average
OPN and Insulin Resistance
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greater in the OPN KO mice. Hepatic glucose output (HGO)
during the clamp of NC-fed OPN KO mice was 52% lower
compared to NC-fed WT mice. In the HFD-fed groups, OPN KO
mice were protected from the severe HFD-induced decrease in
Ginf (73%) and GDR (57%) and increase in HGO (66%) that we
observed in WT mice. There was no significant difference in the
basal glucose turnover rate (HGO=GDR) between WT and OPN
KO mice (15.962.2 mg/kg/min and 16.262.5 mg/kg/min,
respectively), nor between WT mice and HFD-fed WT mice
(15.761.9 mg/kg/min). The clamp data indicate that the absence
of OPN leads to improved hepatic insulin sensitivity when mice
are fed NC and protection from hepatic and skeletal muscle insulin
resistance when mice are fed HFD.
In order to examine the effects of OPN KO on insulin signal
transduction in HFD-fed mice, we conducted in vivo acute insulin-
stimulation studies in the groups. Acute insulin-stimulated skeletal
muscle and adipose tissue Akt phosphorylation results from HFD-
fed mice are shown in Figure 3 and further demonstrate that
HFD-fed OPN KO mice are more insulin sensitive that WT mice.
Insulin-stimulated Akt phosphorylation in muscle was 58% greater
in OPN KO mice compared to WT mice. Insulin-stimulated Akt
phosphorylation was 73% greater in eWAT from OPN KO mice
compared to WT mice but was not different between the strains in
scWAT. These results are interesting in light of the fact that
visceral adipose depots (e.g. eWAT) are much more susceptible to
diet-induced insulin resistance than subcutaneous adipose depots.
Aside from differences in insulin sensitivity detected by
euglycemic hyperinsulinemic clamp and acute insulin stimulation
studies, we observed many similarities between HFD-induced
changes in WT and OPN KO mice and observed that the two
week HFD model of insulin resistance presents without many
secondary abnormalities observed in longer HFD models. Total
body weight was not different between the mouse strains and was
unchanged by HFD (Table 2). Epidydimal white adipose tissue
(eWAT) fat pad weights increased similarly in all animals on HFD,
total weight and percentage of total body weight, and were not
significantly different between the strains (Table 2). Fasting plasma
insulin levels tended to be higher in the NC- and HFD-fed WT
mice compared to the OPN KO mouse groups, but the differences
were not significant by ANOVA (p=0.068) (Table 2). Fasting
plasma glucose levels were slightly elevated only in the HFD-fed
OPN KO mice. We measured other plasma components in the
four animal groups including OPN, adipokines, cytokines,
chemokines, and lipids (Table 3). With the exception of total
cholesterol, none of the plasma components in Table 3 were
Figure 1. Adipose tissue OPN RNA levels are elevated in obese rats and humans and are suppressed by pioglitazone treatment. (A)
Epididymal white adipose tissue OPN RNA levels from Zucker lean, obese, and pioglitazone-treated obese rats. 6 rats per group. (B) Subcutaneous
white adipose tissue OPN RNA levels in lean subjects with normal insulin sensitivity and obese subjects with insulin resistance, before (black bars) and
after (grey bars) pioglitazone treatment. 4–7 subjects per group. Values are averages 6 standard error. * p,0.05 vs lean; # p,0.05 vs obese, before
treatment. (C) Correlation between baseline adipose tissue OPN RNA levels and Rd in lean (filled symbols) and obese subjects (open symbols).
doi:10.1371/journal.pone.0013959.g001
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plasma cholesterol was elevated in both mouse strains fed HFD
but was slightly lower in the OPN KO mice. Plasma OPN was not
elevated after HFD in the mouse groups (Table 3).
In several models of diet-induced insulin resistance, triglyceride
accumulation is observed in muscle and liver. Table 3 shows that
triglyceride levels were slightly, but significantly, lower in skeletal
muscle from NC-fed OPN KO mice compared to WT mice.
There was no difference in muscle triglyceride between the HFD-
fed strains, neither was there a significant increase in triglyceride as
a result of HFD. Liver triglyceride levels tended to increase in the
HFD-fed WT and OPN KO mice, but this trend was not
significant and was not different between the strains.
HFD-induced adipocyte hypertrophy and
hyperleptinemia are blunted in OPN KO mice
We examined histological sections of the eWAT and subcuta-
neous WAT (scWAT). We observed that HFD-induced adipocyte
hypertrophy in eWAT and scWAT from OPN KO mice was
blunted 23% and 30%, respectively, compared to WT mice
(Figure 4A&B). We did not observe any gross differences in
extracellular matrix or other non-adipocyte cell structures when
comparing the groups. Although eWAT fat pad mass was not
significantly different between the HFD-fed strains (Table 2),
eWAT mass and cell size were significantly correlated (Figure 4C).
To demonstrate that the difference in insulin resistance between
HFD-fed WT and OPN KO mice is not solely due to differences
in their adipocyte cell size, we normalized the GDR values of the
groups to their paired eWAT adipocyte cell size values (Figure 4D).
Even after this normalization, there remains a dramatic difference
in insulin sensitivity between HFD-fed WT and OPN KO mice.
HFD caused increased plasma leptin levels in WT mice (4.6-
fold) and that this was 45% blunted in OPN KO mice (Figure 5A).
Again, although fat pad mass was not significantly different
between the HFD-fed WT and OPN KO mice (Table 2), plasma
leptin levels significantly correlated with eWAT adipocyte size
(Figure 5B). This correlation supports our histological observation
that adipocyte hypertrophy was blunted in the HFD-fed OPN KO
mice, as plasma leptin levels have been shown to correlate with
adipocyte size and fat mass in multiple species models of obesity
[38]. We examined the eWAT and scWAT histological sections
for adipose tissue macrophages using the macrophage-specific
marker Mac-2. Mac-2 staining has previously been shown to
increase in adipose tissue from obese mice and humans [39]. We
did not detect any crown-like structures or differences in the
number of Mac-2-stained cells when comparing sections from NC-
Figure 2. OPN KO mice are protected from HFD-induced insulin resistance. Euglycemic hyperinsulinemic clamp study results are shown. (A)
Ginf, (B) GDR, and (C) HGO rates in WT (black bars) and OPN KO (grey bars) mice fed normal chow or HFD. Values are averages 6 standard error. 7–9
mice per group. * p,0.05 vs diet-matched WT, # p,0.05 vs strain-matched, normal chow.
doi:10.1371/journal.pone.0013959.g002
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further examined adipose tissue macrophage content using the
more-comprehensive technique of fluorescence-activated cell
sorting (FACS).
HFD-induced adipose tissue macrophage infiltration and
inflammation is absent in OPN KO mice
Adipose tissue is the site of localized macrophage infiltration
and inflammation in obesity so, we examined macrophage content
and cytokine protein levels in this tissue. We measured adipose
tissue macrophage infiltration in eWAT-derived stromal vascular
cells (SVCs) using FACS. The SVC fraction is heterogeneous cell
population that includes immune-type cells, endothelial cells, and
pre-adipocytes. FACS is a more sensitive and comprehensive
method of detecting the distribution of specific cells types in
adipose tissue compared to immuno-histochemical (IHC) methods.
Cellular contents from the entire fat pad are used for FACS
analyses in contrast to only micro-sections of whole tissue used for
IHC analyses. In addition, co-expression of markers on single cells
can easily be measured by FACS. Macrophages co-expressing the
markers F4/80, CD11b and CD11c are increased in adipose tissue
after HFD and these cells are pro-inflammatory, M1-type
macrophages [11,40–42]. We measured the percentage of live
adipose tissue SVCs that express F4/80, CD11b and/or CD11c
and the percentage that express all three markers, i.e., F4/
80+CD11b+CD11c+ macrophages, in our mouse groups. The
percentage of adipose tissue-derived F4/80+CD11b+CD11c+
SVCs was increased in HFD-fed WT mice fed HFD compared
to NC-fed WT mice (Figure 6A). In contrast, adipose tissue-
derived SVCs isolated from HFD-fed OPN KO mice exhibited no
change in the percentage of SVCs expressing all three markers,
F4/80+CD11b+CD11c+, compared to NC-fed OPN KO mice.
Interestingly, we found that the percent of adipose tissue
macrophages (F4/80+CD11b+ SVCs) that were M1-type (also
CD11c+) increased significantly by 2 week and 4 week HFD
(Figure 6B). This HFD-induced enrichment for M1-type cells in
the total macrophage population was not observed in OPN KO
adipose tissue. These data reveal that normal HFD-feeding-
induced adipose tissue macrophage infiltration does not occur in
OPN KO mice.
We also measured cytokine protein levels in eWAT lysates from
WT and OPN KO mice fed NC or HFD for two weeks. In eWAT
lysates from WT mice fed HFD, we detected significantly elevated
levels of IL-1b, IL-12p70, IFNc, IL-6, and IL-10 (Figure 7). Cxcl1
(KC) and TNFa levels also tended to increase after HFD in WT
mice but this increase did not reach statistical significance. HFD-
fed OPN KO mice were completely protected from increases in
eWAT lysate IL-1b, IL-12p70, IFNc, IL-6, IL-10, Cxcl1 and
TNFa levels. Together with our FACS data, it’s clear that OPN
KO mice are protected from HFD-induced adipose tissue
macrophage infiltration and inflammation.
HFD alters OPN isoform expression in adipose tissue
Although SVC expression of OPN mRNA was elevated after
two- and four-week HFD in WT mice (Figure 6B), OPN protein
levels, measured by ELISA, were unchanged in whole adipose
tissue lysates from 2-week HFD-fed WT mice (Figure 7). In
contrast, chronic models of HFD feeding and obesity have
increased levels of adipose tissue OPN protein [15,27,37]. Because
OPN in known to exhibit diverse alterations in isoform expression
that are related to its biological activity, we evaluated potential
OPN protein isoform expression changes induced by our short-
term HFD protocol using SDS-PAGE/western blotting. HFD
feeding induced significant alterations in OPN isoform expression
(Figure 8A&B). NC-fed mice predominantly expressed a 40kD
isoform and HFD-fed mice predominantly expressed a 55kD
Figure 3. Insulin-stimulated Akt phosphorylation is enhanced
in HFD-fed OPN KO mice. Phosphorylation of Ser
473-Akt (pS-Akt)
after 15 min in vivo insulin stimulation was measured in tissue lysates
by ELISA and western blotting. Ratios of pS-Akt:total Akt protein are
normalized to basal levels in WT controls. WT fed HFD (black bars), OPN
KO fed HFD (grey bars). A representative western blot from each tissue
is shown directly above the matching bar graph. Muscle – gastrocne-
mius, scWAT – subcutaneous white adipose tissue, eWAT – epididymal
white adipose tissue. Values are averages 6 standard error. 8–10 mice
per group. * p,0.05 vs WT.
doi:10.1371/journal.pone.0013959.g003
Table 2. Mouse strain characteristics.
WT NC WT HFD OPN KO NC KO HFD
Whole body weight, g 27.5 (0.7) 29.3 (0.9) 27.2 (0.8) 28.7 (0.7)
Epididymal fat pad weight, g 0.24 (0.02) 0.71 (0.08)# 0.26 (0.02) 0.60 (0.05)#
Epididymal fat pad mass, % body weight 0.87 (0.08) 2.37 (0.25)# 0.95 (0.08) 2.13 (0.14)#
Fasting plasma glucose, mg/dL 162 (6) 172 (11) 177 (9) 203 (8)*
Fasting plasma insulin, ng/mL 1.65 (0.44) 1.89 (0.78) 0.62 (0.17) 0.61 (0.05)
Data are averages 6 standard error. 7–10 mice per group.
*p,0.05 vs diet-matched WT,
#p,0.05 vs strain-matched NC.
doi:10.1371/journal.pone.0013959.t002
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the groups (Figure 8C), in agreement with our ELISA data
(Figure 7). Different OPN isoforms can be generated by
heterogeneous splicing, translation, and post-translational modifi-
cation which can vary by tissue and physiological condition and
can alter its activity systems [23–28].
OPN KO and HFD feeding alter bone marrow stromal cell
osteogenic and adipogenic differentiation potential
Bone marrow-derived mesenchymal stromal cells (BMSCs) are
multi-potent and can differentiate along osteogenic, adipogenic
and chondrogentic pathways [43]. OPN is a key regulator of bone
biology and appears, based on our studies, to also be a key
regulator of adipocyte biology. Therefore, we analyzed whether
the absence of OPN expression and/or HFD would affect the
propensity of BMSCs to differentiate through osteogenic and
adipogenic pathways. We harvested BMSCs from the mouse
groups and subjected them in parallel to either an osteogenic or
adipogenic protocol. Progression through each differentiation
program was measured by expression of marker osteoblast genes
alkaline phosphatase (Akp2) and osterix (Osx) and the adipocyte
gene PPARc (Figure 9). Expression of the Akp2 and Osx during
osteogenic differentiation was significantly greater in OPN KO
BMSCs than in WT BMSCs (Figure 9A). HFD significantly
blunted WT BMSC osteogenic differentiation but had no effect on
OPN KO osteogenic differentiation (see inserts in Figure 9A).
Expression of PPARc during the adipogenic protocol was nine
orders of magnitude greater in WT BMSCs compared to that in
OPN KO BMSCs (Figure 9B). HFD significantly enhanced WT
BMSC adipogenic differentiation (1000-fold more PPARc expres-
sion) but had no effect on OPN KO adipogenic differentiation. It
is striking that the two week HFD had such a profound effect on
WT BMSC osteogenic and adipogenic differentiation potential
after ex vivo culture for more than four weeks. It is possible that
HFD exposure programs a differentiation potential bias in the
BMSCs in vivo. Similar counter-effects of a pro-atherosclerosis diet
on BMSC osteogenesis and adipogenesis have been observed [44].
Our data show that OPN deletion enhances osteogenic and
inhibits adipogenic differentiation potential of BMSCs in vitro and,
conversely, that HFD inhibits osteogenic and enhances adipogenic
differentiation potential of BMSCs in vitro.
Discussion
Insulin resistance is associated with chronic low grade
inflammation in adipose tissue. Although the known biological
roles of OPN include regulating inflammation, a role for OPN in
regulating adipose tissue biology and/or whole body metabolism
has recently been described [14,15]. We found that OPN RNA
expression was elevated in adipose tissue of obese insulin resistant
rats and humans, was correlated with Rd in humans, and was
normalized after TZD treatment. In global transcriptional
profiling analyses, OPN is one of many inflammatory genes
over-expressed in adipose tissue from humans [20] and five
different mouse models of obesity [36]. OPN is expressed in many
cell types [18]. OPN over-expression in obese adipose tissue is
attributable primarily to macrophages and other stromal vascular
cells [15,27] but OPN is also expressed in adipocytes ([15,45] and
our data not shown). OPN expression is elevated in response to
leptin, cytokines, and lipid modulators and is down-regulated by
PPARc and LXR ligands in human adipose tissue and other cell
Table 3. Tissue and plasma components.
WT NC WT HFD KO NC KO HFD
Plasma Cytokines, etc.
OPN (ng/mL) 5108 (382.4) 5772 (568.5) N.D. N.D.
ACRP30 (ug/mL) 22.7 (1.7) 27.9 (4.0) 25.6 (3.2) 35.6 (6.3)
MCP-1 (pg/mL) 42.63 (1.1) 43.87 (14.2) 73.49 (12.8) 64.0 (9.6)
IL-1b (pg/mL) 43.1 (5.1) 22.4 (6.0)# 36.0 (2.8) 22.2 (2.0)
IL-12p70 (pg/mL) 59.5 (7.3) 39.4 (10.4) 50.6 (2.6) 37.8 (4.6)
IFNc (pg/mL) 14.1 (1.7) 11.0 (3.4) 12.9 (0.8) 9.8 (1.3)
IL-6 (pg/mL) 218.5 (16.5) 179.7 (48.2) 187.1 (11.1) 167.0 (24.8)
KC (CXCL-1) (pg/mL) 84.4 (5.7) 67.2 (9.9) 93.5 (14.9) 63.5 (3.7)
IL-10 (pg/mL) 130.2 (1.1) 129.9 (1.6) 135.9 (1.9) 129.4 (1.1)
TNFa (pg/mL) 38.7 (3.5) 31.5 (4.1) 41.7 (3.2) 31.7 (1.2)
Resistin (pg/mL) 826.9 (66.5) 762.5 (92.7) 1067.0 (115.5) 788.8 (38.4)
RBP4 (a.u.) 2.3 (0.5) 2.1 (0.4) 1.9 (0.5) 2.0 (0.4)
Tissue and plasma Lipids
Total plasma cholesterol (mg/dL) 78.4 (2.2) 147.8 (20.0)# 78.9 (2.5) 127.0 (3.6)*#
Plasma triglycerides (mg/dL) 31.0 (3.5) 28.8 (4.2) 39.2 (6.5) 24.6 (1.6)#
Plasma free fatty acids (mmol/L) 0.433 (0.025) 0.454 (0.099) 0.418 (0.024) 0.370 (0.027)
Skeletal muscle triglycerides (mg/dL) 15.3 (1.0) 15.7 (2.9) 12.5 (0.8)* 14.7 (0.9)
Liver triglycerides (mg/dL) 6.7 (1.1) 9.7 (1.3) 7.2 (1.0) 8.5 (1.2)
Data are averages 6 standard error. 7–10 mice per group.
*p,0.05 vs diet-matched WT,
#p,0.05 vs strain-matched NC.
N.D. - not detected.
doi:10.1371/journal.pone.0013959.t003
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13959Figure 4. Adipocyte hypertrophy is blunted in OPN KO mice. (A) Representative histological images of eWAT from mouse groups. (B)
Quantitation of subcutaneous WAT (scWAT) and epididymal WAT (eWAT) adipocyte size. WT scWAT (black bars), WT eWAT (dark grey bars), OPN KO
scWAT (light grey bars), OPN KO eWAT (white bars). 7 mice per group. Values are averages 6 standard error. * p,0.05 vs diet-matched WT, # p,0.05
vs strain-matched, normal chow. (C) Correlation of eWAT fat pad weight and adipocyte size in HFD-fed WT and OPN KO mice. WT (filled symbols),
OPN KO (open symbols). 7 mice per group. (D) GDR normalized to eWAT cell size in HFD-fed WT (black bars) and OPN KO (grey bars) mice. 5–6 mice
per group. Values are averages 6 standard error. * p,0.05 vs WT.
doi:10.1371/journal.pone.0013959.g004
Figure 5. HFD-induced elevation of plasma leptin levels is blunted in OPN KO mice. (A) Leptin levels were measured by ELISA. WT (black
bars) and OPN KO (grey bars) mice fed normal chow or HFD. Values are averages 6 standard error. 8–10 mice per group. * p,0.05 vs diet-matched
WT, # p,0.05 vs strain-matched, normal chow. (B) Correlation of plasma leptin levels with eWAT adipocyte size in WT and OPN KO mice fed HFD. WT
(filled symbols), OPN KO (open symbols). 7 mice per group.
doi:10.1371/journal.pone.0013959.g005
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[20] and current findings suggest that normalization of OPN
expression in adipose tissue may play a key role in TZD-mediated
sensitization by reducing inflammation. Kiefer et al. have just
published that an OPN-neutralizing antibody acutely adminis-
tered in vivo inhibits diet-induced insulin resistance and inflamma-
tion [14].
We investigated the role of OPN in the early development of
insulin resistance using a 2-4 week HFD feeding model [12]. Notably,
the two week HFD was not associated with detectable changes in
body weight, liver or skeletal muscle triglyceride, macrophage crown-
like structures inadipose tissue, plasmaFFA ortriglyceride,or plasma
inflammatory markers (with the exception of leptin). Our reported
phenotypesofearlyonset highfat feeding (herein and [12]) are similar
to those observed by Park, et al. in their timecourse study of HFD-
induced insulin resistance [7]. Two-week HFD induced severe
hepatic and skeletal muscle insulin resistance in WT mice, and
hyperinsulinemia, hypercholesterolemia, and fat pad expansion in
both mouse strains. OPN KO mice were protected from HFD-
inducedhepaticandskeletalmuscleinsulinresistanceandhadgreater
hepatic insulin sensitivity than WT mice when fed NC. OPN is over-
expressed in nonalcoholic steatohepatitis (NASH) liver [47] and in
liver from obese humans and mice, the level of which correlates with
steatosis [37]. The OPN KO liver phenotype that we observe is
supported by recent studies where acute OPN-neutralizing antibody
treatment protected mice from diet-induced liver inflammation but
not steatosis [14]. OPN KO mice also exhibited significantly
enhanced insulin-stimulated skeletal muscle and eWAT Akt
phosphorylation after HFD, compared to WT mice, which
corresponds with their enhanced insulin sensitivity.
HFD increased plasma leptin levels in WT mice and this
increase was blunted in OPN KO mice. We observed similar
differences in the effect of HFD on leptin RNA expression in
adipose tissue from these strains (data not shown). We also
observed that the plasma leptin levels correlated with eWAT
adipocyte size in both WT and OPN KO mice. In several obesity
models, leptin levels are elevated, reflect adipose mass, and
correlate with adipocyte size in humans [38,48,49]. TZDs and
weight loss both reduce plasma leptin levels and adipocyte size
[48,50]. Leptin has inflammatory activity and can activate
secretion of proinflammatory cytokines [38,51]. Leptin induces
Ser-318 phosphorylation of IRS1 in lymphocytes and skeletal
muscle, inhibiting insulin signal transduction in muscle [52].
Cultured hepatocytes from db/db mice increase mRNA and
protein expression of OPN after treatment with leptin and both
the short-form leptin receptor and OPN were critical regulators in
the db/db NASH model [53]. Thus, higher leptin levels in the
plasma and, presumably, adipose tissue of HFD-fed WT mice may
contribute to the multi-tissue insulin resistance we observe in WT
vs. OPN KO mice. Other studies have shown that food and water
intake, CO2 production, O2 consumption, physical activity, and
thermogenesis were not different between the WT and KO strains
fed either NC or HFD ([15] and D.T., D.D.S., A. Wynshaw-Boris,
M. Street, unpublished observations).
Adipocytes from OPN KO mice were significantly less
hypertrophic after HFD than the adipocytes from WT mice.
Decreased HFD-induced hypertrophy of OPN KO adipocytes
may be related to the decreased adipogenic potential of OPN KO
BMSCs compared to WT BMSCs and is discussed in more detail
below. In addition to secreting more leptin, larger adipocytes are
less insulin sensitive, secrete more inflammatory cytokines and
FFAs, and produce more reactive oxygen species and than smaller
adipocytes [54]. We observe decreased insulin sensitivity and
increased pro-inflammatory macrophage content and cytokine
protein in eWAT from HFD-fed WT mice whereas these HFD-
induced effects were absent in OPN KO mice. Increased cytokine
secretion could be attributable to the increased pro-inflammatory
macrophages, adipocytes, and/or other cell types in eWAT such
as endothelial cells and preadipocytes. Leptin and OPN both
induce inflammatory cytokine secretion [18,38] and could be
mediators of the increased cytokine secretion that we observe in
the HFD-fed WT eWAT. Although total eWAT OPN protein did
not change in HFD-fed WT mice, there was a significant HFD-
induced shift in OPN isoform expression. OPN biological activity
is modulated by differential splicing, translation, glycosylation,
phosphorylation, and/or proteolysis that can give rise to various
isoforms, as has been shown in other systems [23–28]. Thus, HFD-
induced OPN isoform change may confer a biological activity to
OPN that is important for initiating adipose tissue macrophage
infiltration. Based on our human and rat expression data (within
and [20]) and on the data of others [15,27,36,37], we know that
OPN expression does increase after chronic obesity and/or HFD.
Figure 6. Inflammatory macrophage content and OPN expression in adipose tissue SVCs are blunted in HFD-fed OPN KO mice. (A)
FACS detection of M1-type, F4/80+CD11b+CD11c+ pro-inflammatory macrophages in adipose tissue SVCs. Data are presented as fold change in the
percentage of live adipose tissue SVCs expressing all three markers (F4/80, CD11b and CD11c) in the HFD vs normal chow (NC) groups. (B) FACS
detection of percent of live adipose tissue SVC F4/80+CD11b+ macrophages that are CD11c+, M1-type. Data are presented as fold change vs strain-
matched normal chow (NC) groups. (C) OPN expression increases in adipose tissue SVCs after HFD feeding in WT mice. SVCs were isolated during
sample preparation for the FACS studies. NC (white bars), 2-week HFD (grey bars), 4-week HFD (black bars). 2–4 mice per group. *p,0.05 vs diet-
matched WT, # p,0.05 vs strain-matched NC, 1 p,0.05 vs strain-matched 2-week HFD.
doi:10.1371/journal.pone.0013959.g006
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relationship between the differentiation of BMSCs into osteoblasts
and adipocytes [43,55,56]. The balance between bone and
adipocyte generation in bone marrow is affected by factors
including aging, osteoporosis, and activation of PPARc. In our
studies, BMSCs isolated from OPN KO mice were significantly
Figure 7. HFD-induced elevation of adipose tissue cytokine levels is blunted in OPN KO mice. Cytokine protein levels were measured in
eWAT lysates from WT (black bars) and OPN KO (grey bars) mice fed normal chow or HFD. Values are averages 6 standard error. 8–10 mice per group.
*p ,0.05 vs diet-matched WT, # p,0.05 vs strain-matched, normal chow.
doi:10.1371/journal.pone.0013959.g007
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PLoS ONE | www.plosone.org 11 November 2010 | Volume 5 | Issue 11 | e13959Figure 8. HFD alters adipose tissue OPN isoform expression. (A) Representative western blot of OPN isoforms with apparent molecular
weights of approximately 40 and 55kD. (B) Paired ratios of 40kD:55kD isoforms in all WT samples. (C) Sum of 40 and 55kD isoforms in all WT samples.
Values are averages 6 standard error. 4–10 mice per group.
# p,0.05 vs normal chow (NC).
doi:10.1371/journal.pone.0013959.g008
Figure 9. OPN KO and HFD effects on osteogenic and adipogenic differentiation of bone marrow stromal cells. BMSCs from the bone
marrow of WT and OPN KO mice fed NC or HFD were cultured for 14 days and then subjected to osteogenic or adipogenic differentiation cocktails for
the number of days shown. (A) Osteogenic differentiation was gauged by Akp2 and OSX RNA expression. Insert bar graphs are data from WT BMSCs
shown separately. (B) Adipogenic differentiation was gauged by PPARc RNA expression. Experiments were conducted in triplicate using BMSCs
isolated from 4 mice per group. Gene expression data for all genes was normalized to GAPDH RNA expression. WT mice fed NC (black bars), WT mice
fed HFD (white bars), OPN KO mice fed NC (dark grey bars), OPN KO mice fed HFD (light grey bars). Values are averages 6 standard error. * p,0.05 vs
diet-matched WT, # p,0.05 vs strain-matched, normal chow.
doi:10.1371/journal.pone.0013959.g009
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WT mice which suggests that OPN is an important regulator of
both differentiation pathways. A similar bone marrow phenotype
was reported in mice expressing a deletion mutant FosB transgene
[57]. Our data correlate with the reports that OPN KO mice have
greater bone mineralization than WT mice [58] and are resistant
to models of bone loss [59,60]. Adipose tissue-derived stromal cells
(ATSCs) and BMSCs have similar gene expression patterns and
osteogenic and adipogenic differentiation potentials [61]. We
speculate that the OPN KO ATSCs, like OPN KO BMSCs, may
be less adipogenic than WT ATSCs. Little is known about the
mechanisms regulating adipocyte hypertrophy. HFD-fed OPN
KO mice have decreased adipocyte hypertrophy compared to WT
mice, which may be due to decreased ability of the adipocytes to
fully differentiate to maturity (reduced hypertrophic capability),
and possible compensatory adipocyte hyperplasia to accommodate
the high lipid load of HFD. Adipocyte hypertrophy and
differentiation require extensive extracellular matrix remodeling
[62–64]. Given the well-characterized role of OPN in extracellular
matrix remodeling, OPN deficiency may impair adipocyte
hypertrophy/differentiation through dysregulation of extracellular
matrix. Notably, the effects of OPN deficiency on in vitro
adipogenic BMSC differentiation suggest that the role of OPN
in insulin resistance and adipocyte biology extends beyond it role
in modulating immune cell function.
We have made the novel observation that two week high fat diet
impedes subsequent in vitro BMSC osteogenic differentiation and
enhances adipogenic differentiation in WT not in OPN KO mice.
In the WT mice, this effect may be mediated by PPARc ligands,
either components or metabolites of the HFD, that have long term
effects on the differentiation potential of BMSCs. This finding
correlates with in vivo published studies relating a balance between
bone marrow adiposity and bone density [43]. Interestingly, the
high fat diet effect on BMSC differentiation potential was not
observed in the OPN KO mice and further suggests that OPN is a
positive regulator of adipogenesis and negative regulator of
osteoblastic differentiation. The adipogenic and osteogenic
differentiation potential of BMSCs from these mouse groups
needs to be explored further using additional markers of
differentiation.
In summary, we find that OPN is a key modulator of the early
onset of high fat diet-induced insulin resistance in liver, muscle and
adipose tissue. Our findings suggest that the mechanism by which
the OPN KO mice are protected from HFD-induced insulin
resistance involves reduced leptin expression, decreased hypertro-
phy of adipocytes, and suppression of inflammatory macrophage
infiltration and cytokine secretion in adipose tissue. OPN
deficiency also alleviates insulin resistance induced after chronic
high fat feeding, in part, by reducing macrophage infiltration into
adipose tissue [15] and acute neutralization of OPN inhibits
obesity insulin resistance and inflammation [14]. OPN is novel
participant in the early pathogenesis of diet-induced insulin
resistance and a modulator of insulin target tissue biology. Our
data and those from the references above strongly suggest that
OPN may be an attractive therapeutic target for the treatment of
human insulin resistance and type 2 diabetes.
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